<DOC>
	<DOCNO>NCT01614652</DOCNO>
	<brief_summary>Treatment ischemic heart failure .</brief_summary>
	<brief_title>A Pivotal Trial Establish Efficacy Long-term Safety Parachute Implant System</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Candidates study must meet ALL follow inclusion criterion : Clinical Age ≥ 18 ≤ 79 year . Body Mass Index ( BMI ) ≤ 40 . Symptomatic ischemic heart failure ( New York Heart Association ( NYHA ) Class III `` ambulatory '' Class IV determine use SAS ) post Myocardial Infarction ( MI ) Left Anterior Descending ( LAD ) territory least 60 day prior enrollment . Patient hospitalize time enrollment . Receiving appropriate medical treatment heart failure accord current American College Cardiology ( ACC ) /American Heart Association ( AHA ) Guideline Update Diagnosis Management Chronic Heart Failure Adult three month prior enrollment . The patient patient 's legal representative inform nature study , agree provision , provide write informed consent approve Institutional Review Board ( IRB ) /Ethics Committee ( EC ) respective clinical site . The patient treat physician agree patient return require postprocedure followup visit . Inclusion Criteria base Imaging : 15 % ≤ Left Ventricular Ejection Fraction ( LVEF ) ≤ 35 % Transthoracic Echocardiogram ( TTE ) . Post LV MI structural heart dysfunction represent LV wall motion abnormality ( WMA ) TTE . Left ventricle must appropriate anatomy ( size morphology ) implant placement use Cardiac Computed Tomography ( CT ) confirm LV gram Candidates exclude study ANY follow condition apply : Clinical Untreated clinically significant coronary artery disease require revascularization . Cardiogenic shock within 72 hour enrollment . Patient receive pacemaker , Implantable Cardioverter Defibrillator ( ICD ) , Cardiac Resynchronization Therapy ( CRT ) within 60 day enrollment . Excessive wall motion abnormality outside anteroapical region . Recent ( within 6 month ) cerebrovascular accident ( CVA ) transient ischemic attack ( TIA ) . End stage renal disease require chronic dialysis . Obstructive Sleep Apnea ( OSA ) : unless compliant CPAP therapy successful surgery . Hemoglobin &lt; 10 g/dl ( female ) , &lt; 12 g/dl ( male ) Creatinine &gt; 2.5mg/dl . Blood dyscrasia , history bleed diathesis coagulopathy , hypercoagulable state . Active peptic ulcer GI bleeding within past 3 month . A known hypersensitivity contraindication aspirin , warfarin , nitinol ( titanium nickel alloy ) , sensitivity contrast medium , adequately premedicated . Ongoing sepsis , include active endocarditis . Life expectancy &lt; 1 year due associate noncardiac comorbid condition currently heart transplant list . Other medical , social , psychological condition opinion Investigator preclude patient appropriate consent . Currently participate investigational drug another device study ( prior primary endpoint reach ) . Female patient childbearing potential positive urine pregnancy test . Anatomical Preexisting prosthetic heart valve mitral aortic position . Valvular stenosis regurgitation ( tricuspid , aortic mitral ) &gt; 2+ . Presence anatomic anomaly ( include severe calcification ) detect cardiac imaging ( echocardiogram , Computed Tomography ( CT ) , LV gram ) preventing unimpeded deployment and/or operation Parachute Implant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Congestive Heart Failure Due LV Systolic Dysfunction</keyword>
</DOC>